The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side). Some good news from a clinical trial conducted by Eli Lilly (LLY 0.54%) boosted the share price of the pharmaceutical giant (by 0.5%) on Wednesday, leaving several rivals in the dust. These included device makers ResMed (RMD -5.97%), whose stock suffered a 6% blow ...